A blood-based composite panel that screens Alzheimer’s disease
Abstract Background Blood tests would be much easier to implement in the clinical diagnosis of Alzheimer’s disease (AD) as minimally invasive measurements. Multiple inspection technologies promoted AD-associated blood biomarkers’ exploration. However, there was a lack of further screening and valida...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-05-01
|
| Series: | Biomarker Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40364-023-00485-6 |
| _version_ | 1797822739276365824 |
|---|---|
| author | Yan Wang Ying Li Yan Li Tingting Li Qi Wang Qigeng Wang Shuman Cao Fangyu Li Jianping Jia |
| author_facet | Yan Wang Ying Li Yan Li Tingting Li Qi Wang Qigeng Wang Shuman Cao Fangyu Li Jianping Jia |
| author_sort | Yan Wang |
| collection | DOAJ |
| description | Abstract Background Blood tests would be much easier to implement in the clinical diagnosis of Alzheimer’s disease (AD) as minimally invasive measurements. Multiple inspection technologies promoted AD-associated blood biomarkers’ exploration. However, there was a lack of further screening and validation for these explored blood-based biomarkers. We selected four potential biomarkers to explore their plasma levels in AD and amnestic mild cognitive impairment (aMCI) and developed a composite panel for AD and aMCI screening. Method The plasma concentrations of soluble low-density lipoprotein receptor-associated protein 1 (sLRP1), Gelsolin (GSN), Kallikrein 4 (KLK4) and Caspase 3 were measured in the discovery and validation cohort. The receiver operating characteristic (ROC) curve was generated to assess the classification panel with the area under the curve (AUC). Results A total of 233 participants (26 CN, 27 aMCI, and 26 AD in the discovery cohort, and 51 CN, 50 aMCI, and 53 AD in the validation cohort) with complete data were included in the study. The plasma concentrations of sLRP1 and Caspase 3 were significantly decreased in AD and aMCI when compared with those in the CN group. Compared with the CN group, the concentrations of KLK4 and GSN were increased in AD, but not in MCI. Interestingly, one of four proteins, sLRP1 in plasma level was higher in Apolipoprotein E (APOE) ε4 non-carriers than that in APOE ε4 carriers, especially among CN and MCI. No significant difference was found between females and males in the plasma levels of four proteins. The composite panel is based on four blood biomarkers accurately classifying AD from CN (AUC = 0.903–0.928), and MCI from CN (AUC = 0.846–0.865). Moreover, dynamic changes in the plasma levels of four proteins exhibited a significant correlation with cognitive assessment. Conclusions Altogether, these findings indicate that the plasma levels of sLRP1, KLK4, GSN and Caspase 3 changed with the progression of AD. And their combination could be used to develop a panel for classifying AD and aMCI with high accuracy, which would provide an alternative approach for developing a blood-based test for AD and aMCI screening. |
| first_indexed | 2024-03-13T10:13:36Z |
| format | Article |
| id | doaj.art-7208bf4bd5e94e3e8382fdeb923c6ca7 |
| institution | Directory Open Access Journal |
| issn | 2050-7771 |
| language | English |
| last_indexed | 2024-03-13T10:13:36Z |
| publishDate | 2023-05-01 |
| publisher | BMC |
| record_format | Article |
| series | Biomarker Research |
| spelling | doaj.art-7208bf4bd5e94e3e8382fdeb923c6ca72023-05-21T11:22:15ZengBMCBiomarker Research2050-77712023-05-011111810.1186/s40364-023-00485-6A blood-based composite panel that screens Alzheimer’s diseaseYan Wang0Ying Li1Yan Li2Tingting Li3Qi Wang4Qigeng Wang5Shuman Cao6Fangyu Li7Jianping Jia8Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, National Clinical Research Center for Geriatric DiseasesInnovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, National Clinical Research Center for Geriatric DiseasesInnovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, National Clinical Research Center for Geriatric DiseasesInnovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, National Clinical Research Center for Geriatric DiseasesInnovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, National Clinical Research Center for Geriatric DiseasesInnovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, National Clinical Research Center for Geriatric DiseasesInnovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, National Clinical Research Center for Geriatric DiseasesInnovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, National Clinical Research Center for Geriatric DiseasesInnovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, National Clinical Research Center for Geriatric DiseasesAbstract Background Blood tests would be much easier to implement in the clinical diagnosis of Alzheimer’s disease (AD) as minimally invasive measurements. Multiple inspection technologies promoted AD-associated blood biomarkers’ exploration. However, there was a lack of further screening and validation for these explored blood-based biomarkers. We selected four potential biomarkers to explore their plasma levels in AD and amnestic mild cognitive impairment (aMCI) and developed a composite panel for AD and aMCI screening. Method The plasma concentrations of soluble low-density lipoprotein receptor-associated protein 1 (sLRP1), Gelsolin (GSN), Kallikrein 4 (KLK4) and Caspase 3 were measured in the discovery and validation cohort. The receiver operating characteristic (ROC) curve was generated to assess the classification panel with the area under the curve (AUC). Results A total of 233 participants (26 CN, 27 aMCI, and 26 AD in the discovery cohort, and 51 CN, 50 aMCI, and 53 AD in the validation cohort) with complete data were included in the study. The plasma concentrations of sLRP1 and Caspase 3 were significantly decreased in AD and aMCI when compared with those in the CN group. Compared with the CN group, the concentrations of KLK4 and GSN were increased in AD, but not in MCI. Interestingly, one of four proteins, sLRP1 in plasma level was higher in Apolipoprotein E (APOE) ε4 non-carriers than that in APOE ε4 carriers, especially among CN and MCI. No significant difference was found between females and males in the plasma levels of four proteins. The composite panel is based on four blood biomarkers accurately classifying AD from CN (AUC = 0.903–0.928), and MCI from CN (AUC = 0.846–0.865). Moreover, dynamic changes in the plasma levels of four proteins exhibited a significant correlation with cognitive assessment. Conclusions Altogether, these findings indicate that the plasma levels of sLRP1, KLK4, GSN and Caspase 3 changed with the progression of AD. And their combination could be used to develop a panel for classifying AD and aMCI with high accuracy, which would provide an alternative approach for developing a blood-based test for AD and aMCI screening.https://doi.org/10.1186/s40364-023-00485-6Alzheimer’s diseaseMild cognitive impairmentBloodBiomarker |
| spellingShingle | Yan Wang Ying Li Yan Li Tingting Li Qi Wang Qigeng Wang Shuman Cao Fangyu Li Jianping Jia A blood-based composite panel that screens Alzheimer’s disease Biomarker Research Alzheimer’s disease Mild cognitive impairment Blood Biomarker |
| title | A blood-based composite panel that screens Alzheimer’s disease |
| title_full | A blood-based composite panel that screens Alzheimer’s disease |
| title_fullStr | A blood-based composite panel that screens Alzheimer’s disease |
| title_full_unstemmed | A blood-based composite panel that screens Alzheimer’s disease |
| title_short | A blood-based composite panel that screens Alzheimer’s disease |
| title_sort | blood based composite panel that screens alzheimer s disease |
| topic | Alzheimer’s disease Mild cognitive impairment Blood Biomarker |
| url | https://doi.org/10.1186/s40364-023-00485-6 |
| work_keys_str_mv | AT yanwang abloodbasedcompositepanelthatscreensalzheimersdisease AT yingli abloodbasedcompositepanelthatscreensalzheimersdisease AT yanli abloodbasedcompositepanelthatscreensalzheimersdisease AT tingtingli abloodbasedcompositepanelthatscreensalzheimersdisease AT qiwang abloodbasedcompositepanelthatscreensalzheimersdisease AT qigengwang abloodbasedcompositepanelthatscreensalzheimersdisease AT shumancao abloodbasedcompositepanelthatscreensalzheimersdisease AT fangyuli abloodbasedcompositepanelthatscreensalzheimersdisease AT jianpingjia abloodbasedcompositepanelthatscreensalzheimersdisease AT yanwang bloodbasedcompositepanelthatscreensalzheimersdisease AT yingli bloodbasedcompositepanelthatscreensalzheimersdisease AT yanli bloodbasedcompositepanelthatscreensalzheimersdisease AT tingtingli bloodbasedcompositepanelthatscreensalzheimersdisease AT qiwang bloodbasedcompositepanelthatscreensalzheimersdisease AT qigengwang bloodbasedcompositepanelthatscreensalzheimersdisease AT shumancao bloodbasedcompositepanelthatscreensalzheimersdisease AT fangyuli bloodbasedcompositepanelthatscreensalzheimersdisease AT jianpingjia bloodbasedcompositepanelthatscreensalzheimersdisease |